Article
PIK3CB Inhibitor GSK2636771 in Cancers With PTEN Mutation/Deletion or Loss of PTEN Protein Expression: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols N and P.
JCO precision oncology - 1 Aug 2025
Janku Filip, Jegede Opeyemi A, Puhalla Shannon L, Konstantinopoulos Panagiotis A, Meric-Bernstam Funda, Zwiebel James A, Gray Robert J, Wang Xin Victoria, McShane Lisa M, Rubinstein Larry V, Patton David R, Williams P Mickey, Hamilton Stanley R, Takebe Naoko, Ghani Sofia, Tricoli James V, Conley Barbara A, Arteaga Carlos L, Harris Lyndsay N, O'Dwyer Peter J, Chen Alice P, Flaherty Keith T
Abstract excerpt
PURPOSE: PTEN loss contributes to aberrant signaling of the phosphatidylinositol 3-kinase (PI3K)/protein kinase B/mammalian target of rapamycin pathway and may confer sensitivity to therapies targeting the PI3K pathway. The PIK3CB inhibitor GSK2636771 demonstrated efficacy in tumors with PIK3CB mutations and may similarly show efficacy in patients with PTEN loss. METHODS: Two nonrandomized, open-label phase II...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.